2021 - How Commercial Insights Can be Used to Maximize an Early Exit
Date2021-08-25
Deadline2021-08-25
VenueXtalks, Canada
KeywordsBiopharmaceutical; Product Development; Commercial Insights
Topics/Call fo Papers
Out-licensing or selling an asset prior to the initiation of pivotal Phase III studies or an NDA submission is always challenging. However, the likelihood of effecting an attractive exit can be significantly enhanced through proactive, strategic planning and the use of commercial insights. To realize an early exit before Phase III or NDA submission, it is critical that sponsors understand the out-licensing environment and develop a cohesive commercial strategy that articulates how the success of the product can be maximized.
This webinar will provide an overview of the commercial insights that should be gathered in the early phases of development and will provide guidance on best practices to use these insights to:
Focus and drive the development process,
Identify the right type of commercial partners, and
Enhance the ability to negotiate better terms for an exit or out-licensing deal.
This webinar will provide an overview of the commercial insights that should be gathered in the early phases of development and will provide guidance on best practices to use these insights to:
Focus and drive the development process,
Identify the right type of commercial partners, and
Enhance the ability to negotiate better terms for an exit or out-licensing deal.
Other CFPs
- Drug Development in a Post-COVID Era
- How to Increase Engagement with Medical and Scientific Posters Using Enhanced Digital Content and Design
- Oncology Trial Complexity: New Tufts CSDD Research and Strategies to Optimize Study Design
- Antimicrobial Resistance: How Clinical Research Can Combat an Ensuing Global Crisis
- The Quality Culture Playbook: How to Build a Quality Culture
Last modified: 2021-07-28 19:28:53